Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
IDO inhibitor
DRUG CLASS:
IDO inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
IO102-IO103 (4)
NLG8189 (4)
Dual TDO/IDO Inhibitor (0)
IDO/TDO dual inhibitor (0)
IO102 (0)
mRNA-4359 (0)
NLG919 (0)
shIDO-ST (0)
IO102-IO103 (4)
NLG8189 (4)
Dual TDO/IDO Inhibitor (0)
IDO/TDO dual inhibitor (0)
IO102 (0)
mRNA-4359 (0)
NLG919 (0)
shIDO-ST (0)
›
Associations
(8)
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600
Melanoma
BRAF V600
Melanoma
pembrolizumab + NLG8189
Sensitive: C2 – Inclusion Criteria
pembrolizumab + NLG8189
Sensitive
:
C2
pembrolizumab + NLG8189
Sensitive: C2 – Inclusion Criteria
pembrolizumab + NLG8189
Sensitive
:
C2
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab + NLG8189
Sensitive: C2 – Inclusion Criteria
nivolumab + NLG8189
Sensitive
:
C2
nivolumab + NLG8189
Sensitive: C2 – Inclusion Criteria
nivolumab + NLG8189
Sensitive
:
C2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
NLG8189
Resistant: C3 – Early Trials
NLG8189
Resistant
:
C3
NLG8189
Resistant: C3 – Early Trials
NLG8189
Resistant
:
C3
PD-L1 expression
Melanoma
PD-L1 expression
Melanoma
pembrolizumab + NLG8189
Sensitive: C3 – Early Trials
pembrolizumab + NLG8189
Sensitive
:
C3
pembrolizumab + NLG8189
Sensitive: C3 – Early Trials
pembrolizumab + NLG8189
Sensitive
:
C3
LDH elevation
Melanoma
LDH elevation
Melanoma
nivolumab + IO102-IO103
Sensitive: C3 – Early Trials
nivolumab + IO102-IO103
Sensitive
:
C3
nivolumab + IO102-IO103
Sensitive: C3 – Early Trials
nivolumab + IO102-IO103
Sensitive
:
C3
PD-L1 negative
Melanoma
PD-L1 negative
Melanoma
nivolumab + IO102-IO103
Sensitive: C3 – Early Trials
nivolumab + IO102-IO103
Sensitive
:
C3
nivolumab + IO102-IO103
Sensitive: C3 – Early Trials
nivolumab + IO102-IO103
Sensitive
:
C3
PD-L1 expression
Head and Neck Cancer
PD-L1 expression
Head and Neck Cancer
pembrolizumab + IO102-IO103
Sensitive: C3 – Early Trials
pembrolizumab + IO102-IO103
Sensitive
:
C3
pembrolizumab + IO102-IO103
Sensitive: C3 – Early Trials
pembrolizumab + IO102-IO103
Sensitive
:
C3
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
pembrolizumab + IO102-IO103
Sensitive: C3 – Early Trials
pembrolizumab + IO102-IO103
Sensitive
:
C3
pembrolizumab + IO102-IO103
Sensitive: C3 – Early Trials
pembrolizumab + IO102-IO103
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login